Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia.
Guangyang WengYu ZhangGuopan YuTingyue LuoSijian YuNa XuZhiqiang SunDongjun LinLan DengXinquan LiangJie XiaoHongyu ZhangZiwen GuoRuoyang ShaoXin DuHua JinQifa LiuPublished in: Journal of internal medicine (2022)
VEN combined with HMA was effective with R/R AML patients, and the response to treatment was associated with genetic characteristics.
Keyphrases
- acute myeloid leukemia
- end stage renal disease
- newly diagnosed
- allogeneic hematopoietic stem cell transplantation
- genome wide
- chronic kidney disease
- acute lymphoblastic leukemia
- prognostic factors
- peritoneal dialysis
- copy number
- diffuse large b cell lymphoma
- gene expression
- hodgkin lymphoma
- replacement therapy
- smoking cessation